Planning Committee

Beth Faiman, PHD, MSN, APN-BC, AOCN, BMTCN, FAAN

Nurse Practitioner

Department of Hematology and Medical Oncology Cleveland Clinic

Cleveland, OH

Beth Sandy, MSN, CRNP

Nurse Practitioner, Thoracic Medical Oncology

Abramson Cancer Center, University of Pennsylvania

Philadelphia, PA

Val R. Adams, PharmD, FCCP, FHOPA, BCOP

Associate Professor, Oncology Specialist

University of Kentucky

Lexington, KY

Leigh Ann Childress MSN, NP, AOCNP

Director of Advanced Practice 

Clearview Cancer Institute

Huntsville, AL

Danielle Roberts PA-C

Physician assistant with the Bone Marrow Transplant team 

Winship Cancer Institute of Emory University

Atlanta, GA

Faculty

Anthony J Olszanski, RPh, MD

Physician

Fox Chase Cancer Center

Philadelphia, PA

Alicia M. Rigby MSN, RN, APRN, AOCNP

Nurse Practitioner

UC Davis Cancer Center

Sacramento, CA

Tanya Uritsky PharmD, BCPP 

Opioid Stewardship Coordinator 

University of Pennsylvania (HUP)

Philadelphia, PA

Michael Lai, 

Nurse Practitioner

Seattle Cancer Care Alliance

Seattle, WA

Kathryn Green, CRNP, MSN

Nurse Practitioner

Abramson Cancer Center, University of Pennsylvania

Philadelphia, PA

Rachel Frankenthal, PA-C

Physician Assistant

UCLA Health

Los Angeles, CA

Jennie M. Goble, PA-C

Instructor in Medicine

 Mayo Clinic

 Rochester, MN

Vanessa Nevins, PA-C, RDMS, RT 

Oncology Physician Assistant

New Haven Smilow Cancer Hospital

New Haven, CT

Suzanne McGettigan CRNP

Oncology Nurse Practitioner and Clinical Manager of Advanced Practice Providers and Nursing

Perelman Center for Advanced Medicine, Abramson Cancer Center

Philadelphia, PA

Bridget Harr CNP

Nurse Practitioner

Cleveland Clinic

Cleveland, OH

Taylor Aldridge

Physician Assistant

Standford Healthcare

Standford, CA

Jennifer Brownell, PharmD

Ambulatory Pharmacy Manager

Clearview Cancer Institute (CCI)

Huntsville, AL

Krisin Daily, MSN, ANP-BC AOCNP

Nurse Practitioner

St. Louis School of Medicine

St. Louis, MO

Kayla Freeman, DNP, APRN, FNP-C  

Nurse Practitioner

Emory Winship Cancer Institute

Atlanta, GA

Lauren Imboden 

Physician Assistant

Atrium Health Wake Forest Baptist

Winston-Salem, NC

Amitkumar Mehta, MD

Physician

University of Alabama

Tuscaloosa, Alabama

Ann Katz, PhD, RN, FAAN, AASECT-Certified Sexuality Counselor

Nurse

CancerCare Manitoba

Winnipeg, Canada

Donna Catamero, ANP-BC, OCN, CCRC

Nurse Practitioner

Icahn School of Medicine at Mount Sinai Hospital

New York, NY

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist

University of Illinois College of Pharmacy

Chicago, IL

Alexandra Palmer, RN, MSN, CRNP

Nurse Practitioner

Emory University’s Winship Cancer Institute

Atlanta, GA

Laura Wood, RN, MSN, OCN 

Nurse

Cleveland Clinic, Taussig Cancer Center

Cleveland, OH

Peter Hakos, PA-C

Physician Assistant

Cleveland Clinic

Cleveland, OH

Lisa Nodzon PhD, APRN, AOCNP

Nurse Practitioner

H. Lee Moffitt Cancer Center and Research Institute

Tampa, FL

Sujata Kane, MS, RD, PA-C

Nurse Practitioner

Winship Cancer Institute, Emory University

Atlanta, GA

DISCLOSURES:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, prior to an activity, Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.

 Planners

 • Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, discloses Advisory Boards with Janssen, GSK and Sanofi, during the past 24 months.
 •  Beth Sandy, MSN, CRNP, discloses participation in Speakers Bureau with Merck, AstraZeneca, Janssen, Amgen, Pfizer, Lilly,  Jazz and Takeda, but Takeda ended, during the past 24 months.
 •  Leigh Ann Childress, MSN, NP, AOCNP, discloses participation in Speakers Bureau  for Merck,  AstraZeneca, Amgen and  Advisory Board with Amgen,  during the past 24 months.

 *Horizon CME has mitigated and resolved all relevant financial relationships

Faculty

 • Anthony J. Olszanski, RPh, MD discloses Advisory Boards with BMS, Repliimune, IO Biotech, Anaveon and Signatera but all these relationships have ended, during the past 24 months.
 •  Tanya Uritsky, PharmD, BCPP discloses Consulting Fees with Novartis, during the past 24 months.
 •  Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP discloses Speakers Bureau with Astellas, during the past 24 months.
 •  Suzanne McGettigan, CRNP, ANP-BC, AOCN, discloses participation in Speakers Bureaus for Pfizer, Bristol Myers Squibb and Regeneron, and discloses Advisory Board with Merck, during the past 24 months.
 •  Beth Sandy, MSN, CRNP, discloses participation in Speakers Bureau with Merck, AstraZeneca, Janssen, Amgen, Pfizer, Lilly, Jazz and Takeda, but Takeda ended, during the past 24 months.
 •  Laura S. Wood, RN, MSN, OCN, discloses participation in Speakers Bureau for AVEO, Exelixis and Merck, during the past 24 
months.
 •  Kristin M. Daly, MSN, ANP-BC, AOCNP, discloses participation on Advisory Board with Amgen, during the past 24 months.
 •  Kathryn L. Green, CRNP, MSN, discloses participation in Speakers Bureau  for AstraZeneca and Aadi Bioscience, during the past 24 months. 
•  Rachel Frankenthal, PA-C, discloses participation on Advisory Boards for Immunogen and GSK, during the past 24 months.
 •  Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, discloses Advisory Boards with Janssen, GSK and Sanofi, during the past 24 months.
 •  Donna Catamero, ANP-BC, OCN, CCRC, discloses participation in Speakers Bureau for Johnson & Johnson. She has served on Advisory Boards for Johnson & Johnson and GSK and has received Consulting Fees from Legend Biotechnology,  during the past 24 months.
 •  Lisa Nodzon PhD, APRN, AOCNP discloses participation in Speakers Bureau for AstraZeneca and Pharmacyclics and has served on Advisory Boards for Novartis, Pharmacyclics, and BeiGeneand has received Consulting Fees from Novartis, AstraZeneca, and Takeda during the past 24 months.
 •  Alexandra Palmer, RN, BSN, FNP discloses Advisory Boards with Incyte but this relationship has ended during the past 24 months. 
•  Peter Hakos, PA-C discloses Speakers Bureau with Sanofi and  owning stock in Pfizer and AbbVie,  but AbbVie relationship has ended, during the past 24 months. 
•  Lauren Imboden, PA-C  discloses being on an Advisory Board with Sanofi and Genzyme,  but these relationships have ended during the past 24 months. 
•  Amitkumar Mehta, MD, discloses participation in Speakers Bureau with Incyte/MorphoSys, BeiGen, Ipsen, Kyowa Kirin, AstraZeneca, BMS, has Consulting Fees and Advisory Boards with Gilead, Seattle Genetics, Incyte, MorphoSys/Incyte, TG Therapeutics, Kyowa Kirin, BeiGen, Roche-Genetech and ADCT and has Contracted Research with Incyte, Takeda, Forty Seven Inc/Gilead, Juno pharmaceuticals/BMS, Celgene/BMS, Innate Pharma, Seattle Genetics, TG Therapeutics, Affimed, Merck, Kite/Gilead, Roche-Genetech, ADC Therapeutics, during the past 24 months.
 
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
 

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

 Other Contributors
 
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

Copyright Information

Copyright© 2025 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be 
reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME